Article Text

Download PDFPDF

49:oral Cost and cost-effectiveness of pediatric oncology unit in Ethiopia
  1. Mizan Kiros1,
  2. Michael Tekle Palm2,
  3. Stephane Verguet3,
  4. Solomon Tessema Memirie4,5,
  5. Mieraf Taddesse Tolla5,
  6. Ole F Norheim3,5
  1. 1Ministry of Health Ethiopia, Addis Ababa, Ethiopia
  2. 2Clinton Health Access Initiative, Addis Ababa, Ethiopia
  3. 3Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA
  4. 4Department of Pediatrics and Child Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
  5. 5Department of Global Public Health and Primary Care, Bergen Centre for Ethics and Priority Setting (BCEPS), University of Bergen, Bergen, Norway


Background Despite the recently increasing global initiatives for childhood cancer, most recommended interventions to improve survival of children with cancers in Low Income Countries (LICs) are classified as either low or medium priority in the recently revised Ethiopia Essential Health Service Package (EEHSP), due to the limitation of local evidence on cost and cost-effectiveness.

Methods We collected historical cost data for the pediatric oncology unit, and all other (eighty-six) departments in Tikur Anbessa Specialized Hospital (TASH) from 8 July 2018 to June 2019, using mixed (dominantly top down) costing approach, and provider perspective. The direct costs of the oncology unit, costs at other relevant clinical departments, and overhead cost share are summed up to estimate the total annual cost. We used data on health outcome from other studies to estimate the net utility gain (DALY averted) of running a pediatric oncology unit compared to doing-nothing scenario. We applied the 50% of GDP/capita as a willingness-to-pay threshold.

Results The annual total cost of running the pediatric oncology unit in TASH during 2018-2019 was USD 797,458 (USD 964 per treated patient). Drugs and supplies (33%), and personnel (32%) constitute a large share of the cost. Sixty two percent of the cost is attributable to Inpatient Department (IPD) services, with the remaining 38% of costs related to Outpatient Department (OPD) services. The cost per DALY averted is USD 461 (range USD 346 to USD 753 on the one-way sensitivity analysis) which lies below the threshold for ‘cost effective’ interventions (USD 477/DALY averted).

Conclusions The provision of pediatric cancer services using a specialized oncology unit is most likely cost effective in Ethiopia and with an additional benefit on equity and financial risk protection. We recommend for reassessing the Childhood cancer treatment priority level decision in the current EHSPE.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: .

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.